Search jobs 04-Jun-2021 iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021
iTeos Therapeutics Announces New Phase 1/2a Data Indicating Antitumor Activity of inupadenant, its Adenosine A2A Receptor Antagonist, at ASCO 2021
Updated results from a dataset of 43 patients showed durable responses and stable disease greater than six months with inupadenant monotherapy in five patients with advanced solid tumors, including previously reported confirmed partial responses in patients with checkpoint-inhibitor resistant melanoma and heavily pretreated castrate-resistant prostate cancer, and a newly reported patient with heavily pretreated non-small cell lung cancer who had stable disease lasting more than 10 months
iTeos to Present at the Jefferies Virtual Healthcare ConferenceCAMBRIDGE, Mass. and GOSSELIES, Belgium, May 26, 2021 (GLOBE NEWSWIRE) iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-onc.
iTeos Therapeutics Inc.: iTeos to Present at the Jefferies Virtual Healthcare Conference
CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 26, 2021 (GLOBE NEWSWIRE) iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that Michel Detheux, PhD, President and Chief Executive Officer, will present at the Jefferies Virtual Healthcare Conference on Wednesday, June 2, 2021 at 8:00 a.m. ET.
A live webcast of the presentation will be available on the Investors section of the company s website at https://www.iteostherapeutics.com. An archived replay will be available for approximately 30 days following the presentation.
Get the latest industry news first when you subscribe to our daily newsletter.
We will never sell or share your information without your consent. See our privacy policy.
(1)
CAMBRIDGE, Mass. and GOSSELIES, Belgium, May 06, 2021 (GLOBE NEWSWIRE) iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Thursday, May 13
th, 2021 to report its first quarter 2021 financial results and provide a corporate update.
Conference Call
Webcast
A live audio webcast will be accessible from the Events page of the Company s IR website at https://investors.iteostherapeutics.com/news-and-events/events. A replay will be available on the Company s website approximately two hours after completion of the event and for 30 days following the call